ASCO: ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
Two posters from the American Society of Clinical Oncology (ASCO) look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.
Read full article »
ASCO is a Virginia-based nonprofit organization that represents and promotes physicians and oncology professionals caring for people with cancer.
Read more